Mallinckrodt touts data for Ofirmev injected acetaminophen

Mallinckrodt Pharmaceuticals (NYSE:MNK) today released results from a clinical pharmacokinetic study evaluating the effect of IV morphine on the absorption of oral acetaminophen, touting the effectiveness of its Ofirmev IV administered acetaminophen over orally administered acetaminophen in adjunct to IV morphine.

The results were presented at this year’s Pain Medicine Meeting of the American Society of Regional Anesthesiology and Pain Medicine in San Diego.

The UK-based company also presented data from 3 retrospective analyses on health economics regarding the use of IV acetaminophen compared to oral acetaminophen for post-operative pain in spine surgery, cholecystectomy and hysterectomy patients.

Get the full story at our sister site, Drug Delivery Business News.

The post Mallinckrodt touts data for Ofirmev injected acetaminophen appeared first on MassDevice.

from MassDevice http://ift.tt/2g4Ooti